Scholar Rock resubmits apitegromab EMA application

Scholar Rock said it resubmitted the marketing authorisation application for apitegromab to the European Medicines Agency for children and adults with spinal muscular atrophy. The company said the filing includes an alternate fill-finish facility and it expects a CHMP opinion in the first half of 2027.